NeuroSearch to present at the Canaccord Adams annual Diabetes and Obesity Conference in New York

- The focus of the presentation will be on tesofensine, the company's highly
efficacious phase II/III anti-obesity drug 

Copenhagen, 4 May 2009 - NeuroSearch has been invited to present at this year's
annual Canaccord Adams Diabetes and Obesity Conference to be held 

Tuesday, 12 May 2009 at 8:00 am - 5:00 pm EST (2:00 pm - 11:00 pm CET)

at the InterContinental Barclay Hotel, 111 East 48th Street, in N.Y.

The presentation will be held by Flemming Pedersen, CEO of NeuroSearch, who
will also conduct 1-on-1 meetings with investors, analysts and other market
participants in relation to the conference. 

In the presentation, Flemming Pedersen will provide broad insight into
NeuroSearch's highly efficacious late-stage anti-obesity drug, tesofensine,
which is ready for Phase III development. In a Phase II Proof of Concept study,
24 weeks' treatment with tesofensine demonstrated a placebo-corrected
weight-loss of approximately 10%. Further, the results of an open-label
extension study have demonstrated a sustainable weight-loss of 13-14% in
average after a combined 48 weeks of treatment with tesofensine. 


From the conference invitation:
Diabetes and obesity have grown into global epidemics. In recognizing the
strong correlation between these two diseases as well as their role in the
development of deadly co-morbidities, this conference is tailored to address
the continuum of care in these diseases providing an insightful value add in
capturing the current and future innovations in the marketplace. 


Contact persons:
Flemming Pedersen, CEO, telephone + +45 4460 8214 or 45 2148 0118
Hanne Leth Hillman, Vice President, Director of Investor Relations & Corporate
Communications, telephone: +45 4460 8212 or +45 4017 5103 


Tesosensine - Novel anti-obesity drug 
Tesofensine is a monoamine reuptake inhibitor which NeuroSearch has evaluated
in Phase II studies with out-standing effect for the treatment of obesity.
After six months of treatment, a weight loss of approx. 10% was obtained
(TIPO-1 study) and a weight loss of approx. 13-14% was seen after 12 months of
treatment (TIPO-4 study). NeuroSearch believes that these results make
tesofensine one of the most effective anti-obesity products in late-stage
development. 

In October 2008, the results from TIPO-1 were published in the highly reputed
international scientific journal The Lancet with the conclusions that
tesofensine can produce a weight loss at least twice that of currently approved
anti-obesity drugs and that it should be further evaluated in Phase III studies
in order to prepare for market registration. 

NeuroSearch has built up a substantial data package supporting the strong
profile of tesofensine. This includes safety data from more than 1,400
individuals having received treatment with tesofensine and of these approx.
1,200 have received relevant therapeutic doses. 

NeuroSearch will decide on the final Phase III development plan following
planned interactions with both the FDA and EMEA in 2009. 


NeuroSearch - Company profile  
NeuroSearch (NEUR) is a Scandinavian biopharmaceutical company listed on Nasdaq
OMX Copenhagen. The core business of the company covers the development of
novel pharmaceutical agents, based on a broad and well-established drug
discovery platform focusing on ion channels and central nervous system (CNS)
disorders. A substantial share of the activities is partner financed through
strategic alliances with Eli Lilly and Company and GlaxoSmithKline and a
license collaboration with Abbott. The drug pipeline comprises seven clinical
(Phase I-III) development programmes: ACR16 for Huntington's disease (Phase
III), tesofensine for obesity (Phase III ready), ABT-894 for ADHD (Phase II) in
partnership with Abbott, ACR325 to treat dyskinesias in Parkinson's disease
(Phase II ready), ACR343 for schizophrenia (Phase II ready), ABT-560 for the
treatment of various CNS disorders (Phase I) in collaboration with Abbott, and
NSD-788 for anxiety/depression (Phase I). In addition, NeuroSearch has a broad
portfolio of preclinical drug candidates and holds equity interests in several
biotech companies.